Boryung Corporation
Financials
Valuation Metrics
Boryung Corporation's Market Cap is ₩7137B. At end of 2025 it was ₩7729B. Ranked #349 of 2,405 in KR market (top 15%), #241 of 778 on KOSPI (top 31%), #35 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 713.75B KRW | KR#349/2,405 Sec#35/231 |
| Revenue | 1.06T KRW | KR#393/2,405 Sec#13/231 |
| Net Income | 120.58B KRW | KR#219/2,405 Sec#12/231 |
| Total Assets | 1.53T KRW | KR#370/2,405 Sec#17/231 |
| Net Assets | 894.81B KRW | KR#317/2,405 Sec#19/231 |
| Employees | 1,646 | KR#168/2,405 Sec#10/231 |
| Value | ||
| P/E | 5.92x | KR#507/2,405 Sec#23/231 |
| P/B | 0.80x | KR#1,325/2,405 Sec#79/231 |
| PEG | 0.02x | KR#202/2,405 Sec#10/231 |
| P/S | 0.67x | KR#1,174/2,405 Sec#57/231 |
| EV/EBITDA | 11.87x | KR#756/2,405 Sec#39/231 |
| FCF Yield | 15.54% | KR#460/2,405 Sec#12/231 |
| Profitability | ||
| ROE | 13.48% | KR#394/2,405 Sec#27/231 |
| ROA | 7.88% | KR#447/2,405 Sec#35/231 |
| Op. Margin | 6.86% | KR#738/2,405 Sec#59/231 |
| Revenue Growth | 3.95% | KR#1,260/2,405 Sec#130/231 |
| Earnings Growth | 279.18% | KR#181/2,405 Sec#10/231 |
| Financial Health | ||
| Debt Ratio | 71.04% | KR#1,226/2,405 Sec#149/231 |
| Total Debt | 199.67B KRW | KR#515/2,405 Sec#27/231 |
| FCF | 110.94B KRW | KR#184/2,405 Sec#10/231 |
| Cash | 50.04B KRW | KR#735/2,405 Sec#41/231 |
| Current Ratio | 1.71x | KR#1,022/2,405 Sec#116/231 |
| Net Debt/EBITDA | 2.06x | KR#839/2,405 Sec#61/231 |
| Dividend | ||
| Div. Yield | 1.93% | KR#935/2,405 Sec#47/231 |
| Div. Growth | 60.00% | KR#200/2,405 Sec#7/231 |
| Performance | ||
| 1Y Return | -5.78% | KR#741/2,405 Sec#42/231 |
| 1M Return | -1.19% | KR#398/2,405 Sec#43/231 |
| From 52W High | -22.96% | KR#252/2,405 Sec#14/231 |
| 1Y MDD | -29.12% | KR#208/2,405 Sec#14/231 |
| Trading | ||
| Volume | 47,553 shares | KR#997/2,405 Sec#106/231 |
| Trading Value | 394.7M KRW | KR#878/2,405 Sec#96/231 |
| Foreign Own. | 5.86% | KR#748/2,405 Sec#68/231 |
| Per Share | ||
| EPS | 1,406 KRW | KR#592/2,405 Sec#41/231 |
| BPS | 10,431 KRW | KR#966/2,405 Sec#66/231 |
Company Info
Boryung, established in 1963 and listed on the securities market in 1988, operates in pharmaceutical manufacturing and sales. The company is expanding its market share in chronic metabolic diseases and oncology with its new drug Kanarb in the professional pharmaceutical sector, achieving results across diverse business divisions. Boryung strives to become a leading healthcare company with high profitability and stable cash generation by maximizing proprietary product capabilities and expanding essential medicine manufacturing infrastructure. Boryung is headquartered in Jongno-gu, Seoul.